News

In this third segment of his interview with Managed Healthcare Executive®, Gorevic discusses whether Teladoc is in competition with primary care physicians, healthcare systems and CVS.

Keytruda gets another indication, the first targeted therapy for advanced prostate cancer is approved, BMS snags approval for Opdualag, the FDA misses PDUFA date for Reblozyl and issues CRLs for sintilimab and Natpara.

Summary: In this second installment of his interview with Managed Healthcare Executive®, Gorevic discusses ambitious goals for increasing per-participant, per-month revenues to $68.

In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.

The longtime CEO of Teladoc discusses the company's deal with Amazon and providing telehealth services via Alexa in this first part of a three-part article series.

As the industry becomes oriented toward value-based care and its focus on high-value outcomes, utilization management must evolve to address the entire patient care journey, often across multiple episodes of care.

Data is shown in a recent American Medical Association survey, which comes as Congress recently extended the availability of telehealth for Medicare patients beyond the current COVID-19 public health emergency.

Tagged with the moniker "late retirees," this group of Medicare first-timers isn’t ready to call it quits. How can you help them? Find out below:

The proposed rules might ratchet down drug costs for Medicare beneficiaries and would set network adequacy standards.

A company-sponsored study found that Theranica’s digital therapeutic Nerivio resulted in a substantial reduction in intake of prescribed pharmacological medications

Court challenges on the independent dispute resolution process. A district court judge has vacated that part of the law nationwide.

But there is no significant difference in rate of hospitalization for major bleeding when Eliquis is compared with Xarelto or warfarin.

In this first of a two-part video series, Jason Warrelmann, global director of Healthcare and Life Sciences at UiPath, addressed the incline of automation in healthcare, why it's necessary for patients and providers and how other healthcare organizations can better overcome the challenges of adopting automation within their health system.

Five years ago, health care providers didn’t see mobile as a priority or a necessary tool in improving the patient experience. The pandemic changed that.

FDA approves first generic of Symbicort for asthma and COPD and first therapy for rare seizure disorder, Rinvoq and Lynparza get nods for new indications, the agency approves a new delivery system for Alzheimer’s therapy, regulators extend review for Opzelura for skin condition and issue CRL for Fasenra for chronic rhinosinusitis.

A recent survey found COVID-19 death rates among both Black and white individuals were higher in areas with more residential segregation, with Black individuals’ death rates being almost twice as high.

Del Doherty, co-founder of Prodigy Rx, discusses how the PBM aims to give payers control so they can lower costs and can improve clinical and return-to-work outcomes.

Amneal is of 35 global companies selected to manufacture and commercialize generic version of COVID-19 treatment Paxlovid.

William Dietz, MD, PhD, Professor and Director of Sumner M. Redstone Global Center for Prevention and Wellness at George Washington University, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.

New data show longer-term benefits from Aduhelm, which was approved last year to treat Alzheimer’s disease.

ICER analyzed two therapies — Cosela and plinabulin — to prevent chemotherapy-induced neutropenia and other myelosuppressive effects. Both moderately increased quality-adjusted life-years.

ICER also reviewed, plinabulin, which is development chemotherapy-induced neutropenia (CIN) and would achieve common thresholds for cost-effectiveness if priced between $1,100 and $1,600 per dose.

Aaron Glatt, MD, Chairman of the Department of Medicine and Chief of Infectious Diseases/Hospital Epidemiologist at Mount Sinai South Nassau and Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.

The toll that Alzheimer’s disease takes on the health of those affected by the disease is enormous. And so is the associated expense.

There’s no guarantee, but physical activity and corralling cardiovascular risk factors and diabetes improve the odds. Health insurers can assist by helping members address the “upstream” social determinants of health.

In this week's episode, Briana Contreras, editor of Managed Healthcare Executive, spoke with Peter Durlach, chief strategy officer of Nuance. The two discussed how artificial intelligence drives value for patients and providers and how AI tools and solutions are helping health systems reach the quadruple aim of care.

Their application to the FDA included data showing that confirmed infections and severe illness were lower among individuals who received a second booster of the Pfizer-BioNTech vaccine.